Ina similar fashion, a small randomized-controlled pilot study of B-cell depletiontherapy in SSc-PAH produced mixed results, with low levels of rheumatoid factor(RF), IL-12, and IL-17 predictive of improvements in 6-minute walk distance afterrituximab therapy [297]. Here, IL17A is linked to systemic sclerosis.